Table: Solasia Pharma -2024 group results (IFRS)

Solasia Pharma KK

12/02/2025 07:01

Feb 12 (Reuters)- 
              Solasia Pharma K. K. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   Year ended      Year ended       Year to         NEXT  
                Dec 31, 2024    Dec 31, 2023    Dec 31, 2025      YEAR    
                   LATEST         YEAR-AGO        COMPANY       COMPANY   
                   RESULTS         RESULT         FORECAST    H1 FORECAST 
  Sales            316 mln         617 mln          1.30                  
                 (-48.7 pct)     (-43.5 pct)    (+310.2 pct)              
  Operating       loss 1.95       loss 1.14     loss 650 mln              
  Pretax          loss 1.96       loss 1.14     loss 650 mln              
  Net             loss 1.94       loss 1.11     loss 650 mln              
  EPS Basic     loss 9.77 yen   loss 6.62 yen  loss 2.98 yen              
  EPS Diluted   loss 9.77 yen   loss 6.62 yen                             
  Ann Div            NIL             NIL            NIL                   
  -Q2 Div            NIL             NIL            NIL                   
  -Q4 Div            NIL             NIL            NIL                   
 
  NOTE - Solasia Pharma K. K.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T